Anvumetostat not checked
Amgen · AMG 193 · MTA Cooperative PRMT5 inhibitor
FollowEvery change as it happens, and a Monday email
Trials
4 active
5 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Comparator Anvumetostat test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: Anvumetostat Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator Anvumetostat test tablet.”In the company’s words, NCT05094336 on ClinicalTrials.gov
- Tested for
- MTAP-deleted NSCLC, Advanced MTAP-null Solid Tumors, Thoracic Tumors, Non-small Cell Lung Cancer, Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
- Main trialPhase 2
- “The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).”In the company’s words, NCT06593522 on ClinicalTrials.gov
- Other names
- AMG 193 · MTA Cooperative PRMT5 inhibitor
Other drugs for MTAP-deleted NSCLC
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 30 NovPhase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 Oct 2026 | A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | |
| Phase 1/2Active, not recruiting | 30 Nov 2026 | A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | |
| Phase 1Active, not recruiting | 31 Oct 2026 | Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | |
| Phase 1Active, not recruiting | 31 Oct 2026 | A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) | |
| Phase 1/2Completed | 25 Feb 2026 | A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026